Clinical characteristics of cases of vaccine-associated paralytic polio documented in the russian federation in 2006–2016
Shakaryan A. K., Tatochenko V. K., Ivanova O. E., Morozova N. S., Chernyavskaya O. P., Eremeeva T. P., Kozlovskaya L. I., Mikhailova Y. M., Erovichenkov A. A.
Инфекционные болезни
Vol.17, Issue1, P. 115-123
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.20953/1729-9225-2019-1-115-123
Аннотация:
In this study, we analyzed 35 cases of vaccine-associated paralytic polio (VAPP) occurred in the Russian Federation in 2006– 2016. Of them, 15 cases were registered in oral polio vaccine recipients and 20 cases were registered in contacts. We evaluated clinical manifestations and the results of laboratory and instrumental examinations. Time between vaccine application and the development of paralysis varied between 10 and 30 days (mean 18.9 ± 6.5 days). The mean age of study participants was 15.0 ± 12.5 months; the majority of them (82.9[%]) were males. In 11 patients, paresis was preceded by bronchitis and pneumonia. The disease had an acute infectious onset with fever, lasting from 1 to 7 days (mean 2.75 ± 1.6 days) with subsequent development of acute flaccid paralysis of one or more limbs and cranial nerve paralysis (5.6[%]). Most frequently, the patients had lower limbs affected (93.9[%]). The analysis of cerebrospinal fluid demonstrated inflammatory changes in 10 out of 11 patients. Si
Ключевые слова:
Acute flaccid paralysis; Clinical manifestations; Oral poliovirus vaccine; Poliovirus infection; Vaccine-associated paralytic polio
oral poliomyelitis vaccine; acute disease; Article; bronchitis; cerebrospinal fluid analysis; child; clinical article; clinical evaluation; clinical examination; clinical feature; cranial nerve paralysis; electromyography; female; fever; flaccid paralysis; human; Human poliovirus 2; hypotrophy; infectious agent; inflammation; laboratory test; limb defect; lower limb; male; motor dysfunction; muscle disease; muscle hypotrophy; nuclear magnetic resonance imaging; paralytic poliomyelitis; paresis; pneumonia; preschool child; recipient; Russian Federation; spinal cord disease; vaccination reaction; vaccine associated paralytic polio; vaccine associated paralytic polio
Язык текста: Английский
ISSN: 2414-9691
Shakaryan A. K.
Tatochenko V. K.
Ivanova O. E. Ol`ga Evgenyevna 1955-
Morozova N. S.
Chernyavskaya O. P. Ol`ga Pavlovna 1969-
Eremeeva T. P.
Kozlovskaya L. I. Lyubov` Igorevna 1984-
Mikhailova Y. M.
Erovichenkov A. A. Aleksandr Anatolyevich 1957-
Шакарян А. К.
Таточенко В. К.
Иванова О. Е. Ольга Евгеньевна 1955-
Морозова Н. С.
Чернявская О. П. Ольга Павловна 1969-
Еремеева Т. П.
Козловская Л. И. Любовь Игоревна 1984-
Михаилова Y. М.
Еровиченков А. А. Александр Анатольевич 1957-
Clinical characteristics of cases of vaccine-associated paralytic polio documented in the russian federation in 2006–2016
Текст визуальный непосредственный
Инфекционные болезни
ООО "Издательство "Династия"
Vol.17, Issue1 P. 115-123
2019
Статья
Acute flaccid paralysis Clinical manifestations Oral poliovirus vaccine Poliovirus infection Vaccine-associated paralytic polio
oral poliomyelitis vaccine acute disease Article bronchitis cerebrospinal fluid analysis child clinical article clinical evaluation clinical examination clinical feature cranial nerve paralysis electromyography female fever flaccid paralysis human Human poliovirus 2 hypotrophy infectious agent inflammation laboratory test limb defect lower limb male motor dysfunction muscle disease muscle hypotrophy nuclear magnetic resonance imaging paralytic poliomyelitis paresis pneumonia preschool child recipient Russian Federation spinal cord disease vaccination reaction vaccine associated paralytic polio vaccine associated paralytic polio
In this study, we analyzed 35 cases of vaccine-associated paralytic polio (VAPP) occurred in the Russian Federation in 2006– 2016. Of them, 15 cases were registered in oral polio vaccine recipients and 20 cases were registered in contacts. We evaluated clinical manifestations and the results of laboratory and instrumental examinations. Time between vaccine application and the development of paralysis varied between 10 and 30 days (mean 18.9 ± 6.5 days). The mean age of study participants was 15.0 ± 12.5 months; the majority of them (82.9[%]) were males. In 11 patients, paresis was preceded by bronchitis and pneumonia. The disease had an acute infectious onset with fever, lasting from 1 to 7 days (mean 2.75 ± 1.6 days) with subsequent development of acute flaccid paralysis of one or more limbs and cranial nerve paralysis (5.6[%]). Most frequently, the patients had lower limbs affected (93.9[%]). The analysis of cerebrospinal fluid demonstrated inflammatory changes in 10 out of 11 patients. Si